LLY vs TERN

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Score Change Explanation: The drastic score reduction from 70/100 to 10/100 is due to the fundamental change in Terns Pharmaceuticals' investment profile. On March 25, 2026, Merck agreed to acquire TERN for $53/share cash. This acquisition eliminates TERN's independent 10x growth potential, which was the core thesis of the previous analysis. For existing shareholders, the upside is now capped at t...